---
title: "Analyst Reiterates Buy on Lifecore Despite Weak Q1, Citing Confidence in 2026 Targets and Attractive Risk-Reward"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285413943.md"
description: "William Blair analyst Max Smock has maintained a Buy rating on Lifecore (LFCR) despite weak Q1 results, citing confidence in the company's 2026 targets and an attractive risk-reward profile. Although Q1 revenue and adjusted EBITDA fell short of expectations, management's reaffirmation of 2026 goals indicates a positive medium-term outlook. Smock highlights the upcoming earnings call as crucial for clarifying the quarterly shortfall and strategies for achieving future guidance. He acknowledges risks but believes the stock remains a strong buy. Craig-Hallum also reiterated a Buy rating on Lifecore."
datetime: "2026-05-06T16:36:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285413943.md)
  - [en](https://longbridge.com/en/news/285413943.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285413943.md)
---

# Analyst Reiterates Buy on Lifecore Despite Weak Q1, Citing Confidence in 2026 Targets and Attractive Risk-Reward

William Blair analyst Max Smock has reiterated their bullish stance on LFCR stock, giving a Buy rating yesterday.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Max Smock has given his Buy rating due to a combination of factors, even though Lifecore’s first-quarter revenue and adjusted EBITDA fell well short of both his and consensus expectations. He notes that the stock has sold off on the weak print, yet management has reiterated its 2026 targets for revenue and profitability, signaling continued confidence in the medium-term outlook.

Smock emphasizes that the upcoming earnings call should clarify the drivers of the quarterly shortfall and the strategy for still achieving the 2026 guidance, including pipeline progress, cost-efficiency measures, and underlying demand for CDMO and HA manufacturing services. While acknowledging risks such as regulatory quality issues, elevated leverage, customer concentration, and potential FDA-related disruptions, he believes the risk-reward profile remains attractive enough to support a continued Buy recommendation on the shares.

According to TipRanks, Smock is an analyst with an average return of \-15.1% and a 19.44% success rate. Smock covers the Healthcare sector, focusing on stocks such as Icon, Simulations Plus, and Lifecore Biomedical.

In another report released yesterday, Craig-Hallum also maintained a Buy rating on the stock with a $0.00 price target.

### Related Stocks

- [LFCR.US](https://longbridge.com/en/quote/LFCR.US.md)
- [ICLR.US](https://longbridge.com/en/quote/ICLR.US.md)
- [SLP.US](https://longbridge.com/en/quote/SLP.US.md)

## Related News & Research

- [Lifecore Biomedical Q1 revenue falls 34%, misses analyst estimates](https://longbridge.com/en/news/285364305.md)
- [Why This Analyst Thinks Texas Instruments Stock Is on the Path to $1 Trillion](https://longbridge.com/en/news/286957345.md)
- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)
- [Eagle Materials Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call](https://longbridge.com/en/news/286770973.md)
- [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)